Aimmune Therapeutics (AIMT): AR101 PDUFA Date
Finally, we have Aimmune Therapeutics. In this particular case, the Advisory Committee Meeting is over and the PDUFA date is around the corner.
A decision is expected surrounding AR101 as early as Friday of next week. The Advisory Committee Meeting took place on September 13, 2019, with the Committee voting to support approval of the drug. With the positive vote in mind, combined with positive data from clinical trials, there’s a strong chance of approval here.
AR101 is under development as a potential treatment for patients with peanut allergies. In fact, the treatment showed to make it so that those with fatal peanut allergies were tolerable to a clinically meaningful amount of peanut.
Should this approval take place, this could be a blockbuster drug, considering that peanut allergies are some of the most common.
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!